4-aminopyridine has been researched along with Infarction, Middle Cerebral Artery in 3 studies
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rats underwent permanent middle cerebral artery occlusion." | 2.78 | Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion. ( Barrile, DK; Blight, AR; Caggiano, AO; Davenport, MD; Finklestein, SP; Huang, Z; Iaci, JF; Parry, TJ; Ren, J; Wu, R, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honsa, P | 1 |
| Pivonkova, H | 1 |
| Anderova, M | 1 |
| Iaci, JF | 1 |
| Parry, TJ | 1 |
| Huang, Z | 1 |
| Finklestein, SP | 1 |
| Ren, J | 1 |
| Barrile, DK | 1 |
| Davenport, MD | 1 |
| Wu, R | 1 |
| Blight, AR | 1 |
| Caggiano, AO | 1 |
| Wu, KW | 1 |
| Yang, P | 1 |
| Li, SS | 1 |
| Liu, CW | 1 |
| Sun, FY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke[NCT01605825] | Phase 2 | 83 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A TEAE is defined as any adverse event with date of onset (or worsening) on or after the start-date of double-blind treatment through 7 days after the last dose of double-blind treatment.~The severity categories of mild, moderate or severe, are defined below:~Mild is defined as causing no limitation of usual activities~Moderate is defined as causing some limitation of usual activities~Severe is defined as causing inability to carry out usual activities" (NCT01605825)
Timeframe: up to 36 days
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Subjects with any TEAEs | TEAEs Possibly Related to study drug | TEAEs Maximum Severity - Mild | TEAEs Maximum Severity - Moderate | TEAEs Maximum Severity - Severe | TEAEs leading to withdrawal of study drug | TEAEs Serious | Subjects who died | |
| Dalfampridine-ER | 42 | 24 | 29 | 10 | 3 | 5 | 2 | 0 |
| Placebo | 30 | 16 | 16 | 13 | 1 | 1 | 2 | 0 |
1 trial available for 4-aminopyridine and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusion.
Topics: 4-Aminopyridine; Animals; Cross-Over Studies; Disease Models, Animal; Dose-Response Relationship, Dr | 2013 |
2 other studies available for 4-aminopyridine and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Focal cerebral ischemia induces the neurogenic potential of mouse Dach1-expressing cells in the dorsal part of the lateral ventricles.
Topics: 4-Aminopyridine; Adult Stem Cells; Animals; Cell Count; Cell Differentiation; Disease Models, Animal | 2013 |
VEGF attenuated increase of outward delayed-rectifier potassium currents in hippocampal neurons induced by focal ischemia via PI3-K pathway.
Topics: 4-Aminopyridine; Animals; Cerebral Infarction; Disease Models, Animal; Enzyme Inhibitors; Hippocampu | 2015 |